Shared on 22 Aug 25

Fair value Decreased 9.84%

Lexicon Pharmaceuticals' price target was revised down to $2.75 as analysts weigh mixed signals: strong Q2 results and management confidence against heightened reliance on positive upcoming PROGRESS trial data as a near-term share catalyst. Analyst Commentary Upward price target revision follows recent Q2 results exceeding expectations.

Read more

0 votesShare

Shared on 07 Aug 25

Fair value Increased 18%

Despite a sharp downgrade in revenue growth forecasts, Lexicon Pharmaceuticals’ consensus analyst price target has increased notably, supported by a lower future P/E ratio and now stands at $3.05. What's in the News Post-hoc analysis of clinical data showed sotagliflozin reduced hypoglycemia events without increased risk across kidney function subgroups in type 1 diabetes patients using optimized insulin therapy.

Read more

0 votesShare

Shared on 01 May 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 24 Apr 25

AnalystConsensusTarget has increased revenue growth from 1.0% to 10.7% and decreased future PE multiple from 256.2x to 200.3x.

Read more

0 votesShare

Shared on 17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 229.4x to 256.2x.

Read more

0 votesShare

Shared on 09 Apr 25

Fair value Increased 0.39%

AnalystConsensusTarget has decreased revenue growth from 12.5% to 1.0%, increased profit margin from 10.5% to 19.3% and increased shares outstanding growth rate from 0.0% to 0.1%.

Read more

0 votesShare